fluorouracil has been researched along with Esophageal Squamous Cell Carcinoma in 191 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Esophageal Squamous Cell Carcinoma: A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.
Excerpt | Relevance | Reference |
---|---|---|
" In this phase II prospective study, we compared the efficacy and toxicity of DP (docetaxel and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens with concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC) and analyzed the 5-year overall survival (OS) and progression free survival (PFS)." | 9.69 | Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial. ( Chen, B; Hu, Y; Jiang, H; Li, Q; Makelike, K; Xi, M; Zhu, Y, 2023) |
"This phase II trial aimed to assess the safety and efficacy of paclitaxel in combination with cisplatin and 5-fluorouracil (TPF) induction chemotherapy followed by surgery for locally advanced borderline-resectable esophageal squamous cell carcinoma (BR-ESCC)." | 9.51 | Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. ( Fong, WP; Hu, M; Hu, Y; Li, Q; Li, Y; Ren, C; Tan, Q; Wang, D; Wang, Z; Wu, J; Yang, H, 2022) |
"Transient receptor potential vanilloid 2 (TRPV2) was previously shown to play an important role in the maintenance of cancer stem cells, and its specific inhibitor, tranilast, also has potential as a targeted therapeutic agent for esophageal squamous cell carcinoma (ESCC)." | 9.34 | Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC). ( Arita, T; Fujiwara, H; Ikoma, H; Konishi, H; Kosuga, T; Kubota, T; Kudou, M; Kuriu, Y; Morimura, R; Okamoto, K; Otsuji, E; Shimizu, H; Shiozaki, A; Yamamoto, Y, 2020) |
"This phase II trial evaluated the efficacy of cisplatin and fluorouracil (CF)-based combination neoadjuvant chemotherapy on the outcome of patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC)." | 9.24 | Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). ( Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Mori, M; Motoori, M; Satoh, T; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T, 2017) |
"A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment." | 9.20 | Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015) |
"We performed a phase II trial of docetaxel in combination with capecitabine to evaluate the antitumor response, toxicity, and survival in pre-treated patients with advanced esophageal squamous cell carcinoma." | 9.17 | Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. ( Li, X; Lin, S; Lin, W; Lin, Y; Wang, H, 2013) |
"To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma." | 9.16 | [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012) |
"This randomized clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy (cisplatin + 5-fluorouracil + radiotherapy and cisplatin + docetaxel + radiotherapy) regimens in patients with unresectable local advanced oesophageal squamous cell carcinoma." | 9.16 | Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. ( Chen, H; Zhang, T; Zhao, T, 2012) |
"In Japan, standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) includes preoperative chemotherapy with fluorouracil plus cisplatin followed by esophagectomy." | 8.12 | Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. ( Demachi, K; Fujita, T; Fujiwara, H; Kojima, T; Kotani, D; Okunaka, M; Sakashita, S; Yoshino, T, 2022) |
" The current study aimed to retrospectively investigate neoadjuvant radiotherapy with cisplatin and 5-fluorouracil (CF-RT) and radiotherapy with docetaxel and CF (DCF-RT) and compare their treatment outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC)." | 8.12 | Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. ( Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Nakajo, A; Noda, M; Ohtsuka, T; Sasaki, K; Shimonosono, M; Tsuruda, Y; Uchikado, Y, 2022) |
"Salvage concurrent chemoradiotherapy (60 Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy was an effective and safe treatment for locoregional recurrence after curative resection of esophageal squamous cell carcinoma, especially in those approaching a complete response." | 8.12 | Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. ( Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T, 2022) |
"The inclusion criteria were as follows: (1) oesophageal squamous cell carcinoma, (2) a schedule to receive three courses of induction chemotherapy (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 5-fluorouracil 750 mg/m2 days 1-5, every 3 weeks), (3) stage IB-III, (4) 20-75 years old, (5) 0-1 performance status, (6) preserved organ functions and (7) written informed consent." | 8.02 | A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. ( Ando, T; Fujii, H; Hamamoto, Y; Hara, H; Hosokawa, A; Ishikawa, H; Katada, C; Koizumi, W; Kojima, T; Muto, M; Nakajima, TE; Sakamoto, Y; Sugawara, M; Tahara, M; Watanabe, A, 2021) |
" The present study aimed to identify cisplatin (CDDP)/5-fluorouracil (5-FU)-resistant genes in in vitro human esophageal squamous cell carcinoma with transposons." | 7.91 | THUMP domain containing 2 protein possibly induces resistance to cisplatin and 5-fluorouracil in in vitro human esophageal squamous cell carcinoma cells as revealed by transposon activation mutagenesis. ( Fukuda, K; Hayashi, M; Hayashida, T; Kawakubo, H; Kitagawa, Y; Mayanagi, S; Nakamura, R; Suda, K; Wada, N, 2019) |
"5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%." | 7.88 | Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018) |
"This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated with fluorouracil (5FU), cisplatin, and docetaxel." | 7.88 | A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y, 2018) |
"5-Fluorouracil (5-FU) is used for the clinical treatment of esophageal squamous cell carcinomas (ESCCs), yet it also induces chemoresistant cancer cells during treatment, which leads to the failure of the therapy." | 7.85 | A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics. ( Chen, Z; Ge, J; Jiang, H; Li, X; Ma, Q; Shi, Y; Wang, J; Wang, M; Wang, Z; Zhang, C, 2017) |
" This study was aimed to compare the differences in pathologic response and survival between docetaxel/cisplatin and fluorouracil/cisplatin as neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (SCC)." | 7.85 | Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. ( Fu, JH; Li, Y; Liu, MZ; Liu, SL; Xi, M; Yang, YD; Zhang, L; Zhang, P, 2017) |
"Docetaxel, cisplatin and fluorouracil (DCF) is a candidate neoadjuvant chemotherapy (NAC) regimen for esophageal squamous cell carcinoma (ESCC)." | 7.85 | The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. ( Baba, H; Baba, Y; Hiyoshi, Y; Kurashige, J; Sakamoto, Y; Watanabe, M; Yoshida, N, 2017) |
"The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease." | 7.85 | Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017) |
"To retrospectively evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received nonsurgical treatment." | 7.83 | Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. ( Guo, J; Han, X; Hu, G; Liu, L; Tang, N; Wang, Y; Wang, Z; Zhang, Q, 2016) |
"To investigate the effects of nimotuzumab (h-R3) with cisplatin (DDP) or fluorouracil (5-FU) on human esophageal squamous cell carcinoma (ESCC) EC1 cells." | 7.81 | Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells. ( Huo, XQ; Ji, YH; Li, GJ; Li, WW; Lu, P; Mu, YL; Wu, JQ; Yang, XY, 2015) |
"Definitive chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and cisplatin (CDDP) is one of the standard therapies for esophageal squamous cell carcinoma (ESCC); however, inter-individual variations in clinical outcomes have yet to be investigated." | 7.80 | Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Azuma, T; Hirai, M; Kuwahara, A; Miki, I; Minegaki, T; Nakamura, T; Nishiguchi, K; Okuno, T; Omatsu, H; Sakaeda, T; Tamura, T; Yamamori, M, 2014) |
" In this study, 49 Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-fluorouracil (5-FU)/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the effects of genotypes of vascular endothelial growth factor (VEGF) were retrospectively revaluated in terms of prediction of long-term survival." | 7.78 | VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Kuwahara, A; Manabe, Y; Miki, I; Nakamura, T; Nishiguchi, K; Okuno, T; Sakaeda, T; Tamura, T; Yamamori, M, 2012) |
"Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy." | 6.94 | Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. ( Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D, 2020) |
"Paclitaxel is an active agent against oesophageal cancer and it has been proved as a potent radiation sensitiser." | 6.87 | Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2). ( Ai, D; Badakhshi, H; Cao, J; Chen, Y; Deng, J; Fan, J; Fan, M; Huang, G; Li, J; Li, L; Li, Y; Lin, Q; Liu, Q; Luo, H; Ren, W; Wei, S; Wu, K; Yang, H; Ye, J; Zhang, J; Zhao, K; Zhao, W; Zheng, X; Zhou, J; Zhu, H; Zhu, Z, 2018) |
"Forty-six patients with cT4b esophageal cancer, including borderline cT4b lesions, were eligible." | 5.72 | Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil. ( Ihara, K; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T; Takise, S; Yamaguchi, S, 2022) |
"Data from OGSG1003, a randomized phase-II trial comparing two regimens of neoadjuvant chemotherapy, cisplatin and fluorouracil plus Adriamycin and cisplatin and fluorouracil plus docetaxel, for locally advanced esophageal squamous cell carcinoma were used." | 5.69 | The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003. ( Aoyama, S; Doki, Y; Fujitani, K; Hamakawa, T; Hirao, M; Kimura, Y; Makino, T; Miyata, H; Motoori, M; Shiraishi, O; Sugimura, K; Takeno, A; Tanaka, K; Yamasaki, M; Yamashita, K; Yano, M; Yasuda, T, 2023) |
" In this phase II prospective study, we compared the efficacy and toxicity of DP (docetaxel and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens with concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC) and analyzed the 5-year overall survival (OS) and progression free survival (PFS)." | 5.69 | Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial. ( Chen, B; Hu, Y; Jiang, H; Li, Q; Makelike, K; Xi, M; Zhu, Y, 2023) |
"Fluorouracil (FU), platinum (PT), and taxane (TAX) therapy was the standard chemotherapy for esophageal squamous cell carcinoma (ESCC) before the era of anti-programmed death-1 antibodies." | 5.51 | A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404). ( Hirota, M; Kawada, J; Kawakami, H; Kii, T; Kurokawa, Y; Matsuyama, J; Nomura, M; Ohta, T; Sakai, D; Satoh, T; Shimokawa, T; Tsujinaka, T, 2022) |
"Trifluridine/tipiracil monotherapy is feasible and shows modest activity in patients with refractory esophageal squamous cell carcinoma." | 5.51 | Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. ( Hara, H; Hironaka, S; Horimatsu, T; Ishihara, R; Kasai, H; Kato, K; Kawaguchi, A; Kikuchi, O; Kojima, T; Mori, Y; Mukai, K; Muto, M; Tada, H; Tsushima, T; Uozumi, R, 2022) |
"This phase II trial aimed to assess the safety and efficacy of paclitaxel in combination with cisplatin and 5-fluorouracil (TPF) induction chemotherapy followed by surgery for locally advanced borderline-resectable esophageal squamous cell carcinoma (BR-ESCC)." | 5.51 | Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. ( Fong, WP; Hu, M; Hu, Y; Li, Q; Li, Y; Ren, C; Tan, Q; Wang, D; Wang, Z; Wu, J; Yang, H, 2022) |
"Oesophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-associated death in the world and novel therapeutic alternatives are urgently warranted." | 5.43 | Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. ( Bai, L; Chen, DL; Chen, LZ; Ju, HQ; Lu, YX; Mo, HY; Sheng, H; Wang, DS; Wang, F; Wu, QN; Xie, D; Xu, RH; Yu, HE; Yun, JP; Zeng, ZL, 2016) |
"Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains." | 5.39 | Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. ( Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X, 2013) |
"In Japan, esophagectomy after two courses of 5-fluorouracil plus cisplatin is regarded a standard strategy for treating stage II or III esophageal squamous cell carcinoma (ESCC)." | 5.34 | An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus. ( Hattori, N; Hayashi, M; Iwata, N; Kanda, M; Kodera, Y; Koike, M; Nakayama, G; Omae, K; Shimizu, D; Tanaka, C; Yamada, S, 2020) |
"Transient receptor potential vanilloid 2 (TRPV2) was previously shown to play an important role in the maintenance of cancer stem cells, and its specific inhibitor, tranilast, also has potential as a targeted therapeutic agent for esophageal squamous cell carcinoma (ESCC)." | 5.34 | Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC). ( Arita, T; Fujiwara, H; Ikoma, H; Konishi, H; Kosuga, T; Kubota, T; Kudou, M; Kuriu, Y; Morimura, R; Okamoto, K; Otsuji, E; Shimizu, H; Shiozaki, A; Yamamoto, Y, 2020) |
"This phase II trial evaluated the efficacy of cisplatin and fluorouracil (CF)-based combination neoadjuvant chemotherapy on the outcome of patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC)." | 5.24 | Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). ( Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Mori, M; Motoori, M; Satoh, T; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T, 2017) |
"A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment." | 5.20 | Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015) |
"We performed a phase II trial of docetaxel in combination with capecitabine to evaluate the antitumor response, toxicity, and survival in pre-treated patients with advanced esophageal squamous cell carcinoma." | 5.17 | Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma. ( Li, X; Lin, S; Lin, W; Lin, Y; Wang, H, 2013) |
"To compare the efficacy and feasibility of neoadjuvant chemoradiotherapy with docetaxel plus cisplatin or with cisplatin plus fluorouracil in the treatment of local advanced esophageal squamous cell carcinoma." | 5.16 | [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma]. ( Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S, 2012) |
"This randomized clinical study was to assess and compare the efficacy and safety of two chemoradiotherapy (cisplatin + 5-fluorouracil + radiotherapy and cisplatin + docetaxel + radiotherapy) regimens in patients with unresectable local advanced oesophageal squamous cell carcinoma." | 5.16 | Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. ( Chen, H; Zhang, T; Zhao, T, 2012) |
"The standard preoperative treatment for resectable locally advanced esophageal squamous cell carcinoma (LAESCC) in Japan is docetaxel, cisplatin (CDDP), and 5-fluorouracil." | 4.31 | Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. ( Daiko, H; Hashimoto, T; Hirose, T; Honma, Y; Ikeda, G; Ishiyama, K; Itoyama, M; Kadono, T; Kato, K; Oguma, J; Ohara, A; Sekine, S; Yamamoto, S; Yokoyama, K, 2023) |
"We aimed to evaluate the efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy over cisplatin and 5-fluorouracil (CF) in patients with surgically resectable advanced esophageal squamous cell carcinoma (ESCC), using real-world data from 85 esophageal centers." | 4.31 | Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan. ( Doki, Y; Kakeji, Y; Kawakubo, H; Kitagawa, Y; Matsuda, S; Muto, M; Okamura, A; Okui, J; Takemura, R; Takeuchi, H; Watanabe, M, 2023) |
"This study aimed to clarify the impact of the average relative dose intensity (RDI) of neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-NAC) for resectable locally advanced esophageal squamous cell carcinoma (ESCC)." | 4.31 | Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients. ( Hiraki, Y; Imano, M; Kato, H; Momose, K; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T, 2023) |
"In Japan, standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) includes preoperative chemotherapy with fluorouracil plus cisplatin followed by esophagectomy." | 4.12 | Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy. ( Demachi, K; Fujita, T; Fujiwara, H; Kojima, T; Kotani, D; Okunaka, M; Sakashita, S; Yoshino, T, 2022) |
" The current study aimed to retrospectively investigate neoadjuvant radiotherapy with cisplatin and 5-fluorouracil (CF-RT) and radiotherapy with docetaxel and CF (DCF-RT) and compare their treatment outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC)." | 4.12 | Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. ( Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Nakajo, A; Noda, M; Ohtsuka, T; Sasaki, K; Shimonosono, M; Tsuruda, Y; Uchikado, Y, 2022) |
"Salvage concurrent chemoradiotherapy (60 Gy in 30 fractions) with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy was an effective and safe treatment for locoregional recurrence after curative resection of esophageal squamous cell carcinoma, especially in those approaching a complete response." | 4.12 | Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma. ( Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T, 2022) |
"The inclusion criteria were as follows: (1) oesophageal squamous cell carcinoma, (2) a schedule to receive three courses of induction chemotherapy (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 5-fluorouracil 750 mg/m2 days 1-5, every 3 weeks), (3) stage IB-III, (4) 20-75 years old, (5) 0-1 performance status, (6) preserved organ functions and (7) written informed consent." | 4.02 | A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. ( Ando, T; Fujii, H; Hamamoto, Y; Hara, H; Hosokawa, A; Ishikawa, H; Katada, C; Koizumi, W; Kojima, T; Muto, M; Nakajima, TE; Sakamoto, Y; Sugawara, M; Tahara, M; Watanabe, A, 2021) |
"5-Fluorouracil (5-FU) is a chemotherapeutic agent commonly used to treat esophageal squamous cell carcinoma (ESCC), but acquisition of chemoresistance frequently occurs and the underlying mechanisms are not fully understood." | 3.91 | MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1. ( Chan, KT; Chan, KW; Cheung, ALM; Cui, D; Guan, XY; Han, L; Lam, AKY; Law, SYK; Lee, NPY; Li, B; Ma, S; Qin, YR; Tsao, SW; Xu, WW; Zhu, Y, 2019) |
"Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC)." | 3.91 | S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. ( Boku, N; Hirano, H; Honma, Y; Ito, T; Iwasa, S; Kato, K; Okita, N; Shoji, H; Takashima, A, 2019) |
"The aim of this study was to investigate PD-L1 expression and its association with prognosis in esophageal squamous cell carcinoma (ESCC) before and after neoadjuvant chemotherapy (5-fluorouracil and cisplatin, NAC-FP)." | 3.91 | Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8 ( Arimoto, A; Fujita, M; Fukuoka, E; Kakeji, Y; Matsuda, T; Nakamura, T; Oshikiri, T; Sawada, R; Sugita, Y; Suzuki, S; Takiguchi, G; Tanaka, T; Yamashita, K, 2019) |
" The phytochemical curcumin is a potential treatment for Esophageal Squamous Cell Carcinoma (ESCC)." | 3.91 | Tetrahydrocurcumin, Curcumin, and 5-Fluorouracil Effects on Human Esophageal Carcinoma Cells. ( Geusz, ME; Jamasbi, RJ; Pendleton, EG, 2019) |
"This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated with fluorouracil (5FU), cisplatin, and docetaxel." | 3.88 | A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y, 2018) |
"5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%." | 3.88 | Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018) |
"Neoadjuvant chemotherapy (NAC) involving two cycles of cisplatin plus fluorouracil is recommended in Japan as a standard treatment for resectable, locally advanced esophageal squamous cell carcinoma (ESCC)." | 3.88 | Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma. ( Fujiwara, Y; Gyobu, K; Hashiba, R; Ihara, T; Kishida, S; Lee, S; Naka, R; Nishiyama, M; Osugi, H; Takemura, M, 2018) |
"5-Fluorouracil (5-FU) is used for the clinical treatment of esophageal squamous cell carcinomas (ESCCs), yet it also induces chemoresistant cancer cells during treatment, which leads to the failure of the therapy." | 3.85 | A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics. ( Chen, Z; Ge, J; Jiang, H; Li, X; Ma, Q; Shi, Y; Wang, J; Wang, M; Wang, Z; Zhang, C, 2017) |
" This study was aimed to compare the differences in pathologic response and survival between docetaxel/cisplatin and fluorouracil/cisplatin as neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (SCC)." | 3.85 | Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. ( Fu, JH; Li, Y; Liu, MZ; Liu, SL; Xi, M; Yang, YD; Zhang, L; Zhang, P, 2017) |
"The anticancer efficacy of docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy has been reported to be better than that of conventional regimens for advanced or relapsed esophageal squamous cell carcinoma (ESCC), and may become a standard therapy for this disease." | 3.85 | Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. ( Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y, 2017) |
"Docetaxel, cisplatin and fluorouracil (DCF) is a candidate neoadjuvant chemotherapy (NAC) regimen for esophageal squamous cell carcinoma (ESCC)." | 3.85 | The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. ( Baba, H; Baba, Y; Hiyoshi, Y; Kurashige, J; Sakamoto, Y; Watanabe, M; Yoshida, N, 2017) |
" We found that fluorouracil (5-FU)-resistant esophageal squamous cell carcinoma cell lines, established through exposure to increasing concentrations of 5-FU, showed upregulation of Id1, IGF2, and E2F1." | 3.83 | Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance. ( Chan, KT; Chan, KW; Cheung, AL; Guan, XY; He, QY; Law, S; Lee, NP; Li, B; Li, YY; Qin, YR; Tam, PY; Tsao, SW; Xu, WW; Yuen, HF, 2016) |
"To retrospectively evaluate the efficacy and toxicity of definitive concurrent chemoradiotherapy (dCRT) with cisplatinum/paclitaxel versus cisplatinum/5-fluorouracil in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received nonsurgical treatment." | 3.83 | Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients. ( Guo, J; Han, X; Hu, G; Liu, L; Tang, N; Wang, Y; Wang, Z; Zhang, Q, 2016) |
"To investigate the effects of nimotuzumab (h-R3) with cisplatin (DDP) or fluorouracil (5-FU) on human esophageal squamous cell carcinoma (ESCC) EC1 cells." | 3.81 | Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells. ( Huo, XQ; Ji, YH; Li, GJ; Li, WW; Lu, P; Mu, YL; Wu, JQ; Yang, XY, 2015) |
" We examined the effects of celecoxib, a COX-2 inhibitor, in enhancing the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma (ESCC) by reducing the COX-2 activity." | 3.80 | A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. ( Akanuma, N; Akutsu, Y; Hanari, N; Hoshino, I; Hu, X; Isozaki, Y; Komatsu-Akimoto, A; Matsubara, H; Mori, M; Mutallip, M; Qin, W; Yusup, G, 2014) |
"Definitive chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and cisplatin (CDDP) is one of the standard therapies for esophageal squamous cell carcinoma (ESCC); however, inter-individual variations in clinical outcomes have yet to be investigated." | 3.80 | Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Azuma, T; Hirai, M; Kuwahara, A; Miki, I; Minegaki, T; Nakamura, T; Nishiguchi, K; Okuno, T; Omatsu, H; Sakaeda, T; Tamura, T; Yamamori, M, 2014) |
" In this study, 49 Japanese patients with esophageal squamous cell carcinoma (ESCC) were followed up for 5 years after treatment with a definitive 5-fluorouracil (5-FU)/cisplatin (CDDP)-based chemoradiotherapy (CRT), and the effects of genotypes of vascular endothelial growth factor (VEGF) were retrospectively revaluated in terms of prediction of long-term survival." | 3.78 | VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. ( Kuwahara, A; Manabe, Y; Miki, I; Nakamura, T; Nishiguchi, K; Okuno, T; Sakaeda, T; Tamura, T; Yamamori, M, 2012) |
"Patients with disease progression or recurrence after platinum-based chemotherapy and good performance status probably benefit from second-line chemotherapy." | 2.94 | Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. ( Adenis, A; Barbier, E; Borg, C; Breysacher, G; Dahan, L; Desrame, J; Di Fiore, F; Faroux, R; Gaba, L; Laurent-Puig, P; Lièvre, A; Lopez, A; Louafi, S; Louvet, C; Manfredi, S; Metges, JP; Mineur, L; Randrian, V; Roquin, G; Tougeron, D, 2020) |
"Paclitaxel is an active agent against oesophageal cancer and it has been proved as a potent radiation sensitiser." | 2.87 | Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2). ( Ai, D; Badakhshi, H; Cao, J; Chen, Y; Deng, J; Fan, J; Fan, M; Huang, G; Li, J; Li, L; Li, Y; Lin, Q; Liu, Q; Luo, H; Ren, W; Wei, S; Wu, K; Yang, H; Ye, J; Zhang, J; Zhao, K; Zhao, W; Zheng, X; Zhou, J; Zhu, H; Zhu, Z, 2018) |
"Multivariable analyses indicated only esophageal stenosis as a common factor for poor prognosis." | 2.84 | Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303). ( Ando, N; Fukuda, H; Igaki, H; Ishikura, S; Katayama, H; Kato, H; Kato, K; Kawano, T; Kimura, Y; Kitagawa, Y; Kojima, T; Kosugi, S; Nakamura, K; Okabe, H; Okuno, T; Shinoda, M; Toh, Y; Tsubosa, Y; Wakabayashi, M, 2017) |
"For these patients with metastatic esophageal cancer, chemotherapy is generally indicated." | 2.84 | Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. ( Hayata, K; Iwahashi, M; Katsuda, M; Matsumura, S; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H, 2017) |
"This multicenter trial included esophageal cancer patients with clinical T4 disease and/or unresectable regional lymph node metastasis." | 2.80 | Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). ( Ando, N; Fukuda, H; Ishikura, S; Kato, H; Kato, K; Kawano, T; Kimura, Y; Kosugi, S; Minashi, K; Nakamura, K; Okabe, H; Shinoda, M; Toh, Y; Tsubosa, Y, 2015) |
" Adverse events, treatment response and follow-up data were collected." | 2.80 | Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer. ( Li, QL; Qiu, MQ; Wang, T; Yang, JS, 2015) |
"Dose escalation in esophageal cancer based on (18)FDG-PET/CT has been safely achieved up to 70Gy using the SIB technique." | 2.80 | Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer. ( Cai, XW; Feng, W; Fu, XL; Liu, Q; Yao, ZF; Yu, W; Zhang, Q; Zhang, YJ; Zhu, ZF, 2015) |
"The predominant histological types of esophageal cancer are adenocarcinoma and squamous cell carcinoma." | 2.55 | Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. ( Baba, H; Baba, Y; Maehara, Y; Nakashima, Y; Oki, E; Saeki, H; Shigaki, H; Watanabe, M; Yoshida, N, 2017) |
"The treatment for esophageal squamous cell carcinoma (SCC) depends on its etiology." | 2.49 | Treatment options for esophageal squamous cell carcinoma. ( Kato, H; Nakajima, M, 2013) |
"The prognostic impact of postoperative anastomotic leakage (AL) and pneumonia on survival was evaluated." | 1.91 | Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers. ( Doki, Y; Kakeji, Y; Kawakubo, H; Kitagawa, Y; Matsuda, S; Muto, M; Okamura, A; Okui, J; Takemura, R; Takeuchi, H; Watanabe, M, 2023) |
"Forty-six patients with cT4b esophageal cancer, including borderline cT4b lesions, were eligible." | 1.72 | Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil. ( Ihara, K; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T; Takise, S; Yamaguchi, S, 2022) |
"However, patients with esophageal cancer and PD-L1 CPS ≥ 10 may gain the most LYs from initial PPF treatment." | 1.72 | Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis. ( Ding, D; Liu, K; Peng, L; Zhou, Y; Zhu, Y, 2022) |
"She was diagnosed with esophageal cancer (cT3N2M0, stage III)." | 1.56 | A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy. ( Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N, 2020) |
"Esophageal cancer is increasingly common and carries a poor prognosis." | 1.56 | Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. ( Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC, 2020) |
"Niclosamide is an FDA‑approved anthelmintic drug, and may elicit antineoplastic effects through direct STAT3 inhibition, which has been revealed in numerous human cancer cells." | 1.56 | Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents. ( Chen, YK; Hsu, YJ; Lee, MC; Lin, BR, 2020) |
"To investigate the relationship between treatment-related lymphopenia and pathologic response to neoadjuvant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC)." | 1.51 | Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy. ( Hu, Y; Li, Q; Liu, M; Liu, S; Xi, M; Yang, H; Zhao, L; Zhou, S, 2019) |
"The incidence of elderly patients with esophageal cancer (OC) is increasing as the population ages." | 1.51 | Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers. ( Hu, Y; Huang, C; Li, Q; Liu, H; Liu, M; Yuan, Y; Zhang, W; Zhu, Y, 2019) |
"High (≥ 3) dysphagia scores were significantly associated with high incidences of grade 3/4 febrile neutropenia (FN) (79." | 1.51 | Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer. ( Doki, Y; Hagi, T; Kimura, Y; Makino, T; Mori, M; Motoori, M; Nishida, N; Sakai, D; Satoh, T; Tanaka, K; Yamasaki, M, 2019) |
"Esophageal fistula was observed in 28 patients (24%)." | 1.48 | Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study. ( Fukutomi, A; Hamauchi, S; Kawakami, T; Kito, Y; Machida, N; Ogawa, H; Omae, K; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T; Yoshida, Y, 2018) |
"DCF-R treatment for advanced cervical esophageal cancer could be completed by the careful administration; although a strong blood toxicity might occur, this treatment may provide the chance to obtain favorable prognosis with larynx preservation." | 1.48 | Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. ( Heishi, T; Ishida, H; Ito, K; Kamei, T; Konno-Kumagai, T; Maruyama, S; Okamoto, H; Onodera, Y; Sakurai, T; Sato, C; Taniyama, Y; Teshima, J, 2018) |
"Esophageal squamous cell carcinoma (ESCC) exhibits good reactivity to chemoradiation therapy (CRT)." | 1.48 | Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study. ( Baatar, S; Gombodorj, N; Kumakura, Y; Kuriyama, K; Kuwano, H; Miyazaki, T; Nishiyama, M; Sakai, M; Shirabe, K; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T; Yoshida, T, 2018) |
"Myocardial metastasis for esophageal squamous cell carcinoma(ESCC)is relatively rare and it is diagnosed as a part of widespread metastasis in the terminal stage." | 1.48 | [A Case of Myocardial Metastasis of Esophageal Squamous Cell Carcinoma]. ( Akaishi, T; Hakamada, K; Mitsuhashi, Y; Muroya, T; Sato, K; Suzuki, T; Tsuruta, S; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yachi, T; Yoshida, T, 2018) |
"According to recent statistics, esophageal cancer is the eighth most common cancer in Iran." | 1.46 | EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran. ( Abdollahi, A; Aledavoud, SA; Anvari, A; Anvari, K; Forghani, MN; Ghaffarzadegan, K; Memar, B; Seilanian Toussi, M; Shahidsales, S; Sima, HR, 2017) |
"50 patients with advanced esophageal cancer were treated with a continuous infusion of CF, 5-FU, and CDDP, and the short-term effects, adverse reactions, and survival periods after treatment were analyzed." | 1.46 | Continuous infusion of a large dose of CF (folinic acid) and 5-FU combined with CDDP in the treatment of advanced esophageal cancer. ( Cai, HX; Zhu, ZA; Zhu, ZQ, 2017) |
"Esophageal squamous cell carcinoma (ESCC) is the second common cancer in Henan province and is well-known for aggressiveness and dismal prognosis." | 1.46 | All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma. ( Cui, H; Li, D; Li, N; Li, S; Lian, J; Lu, T; Lu, Y; Sang, L; Wang, Y; Yu, JJ; Zhang, L; Zheng, X, 2017) |
"Information about 406 consecutive esophageal cancer patients with resectable disease who underwent surgery with neoadjuvant chemotherapy consisting of cisplatin plus 5-fluorouracil or who underwent definitive CRT was reviewed." | 1.43 | Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis. ( Abe, T; Andoh, M; Kadowaki, S; Kodaira, T; Komori, A; Masuishi, T; Muro, K; Muto, M; Narita, Y; Niwa, Y; Nomura, M; Oze, I; Tachibana, H; Tajika, M; Taniguchi, H; Uemura, N; Ura, T, 2016) |
"Oesophageal cancer is a highly aggressive disease with about 50% of patients presenting with advanced or metastatic disease at initial diagnosis." | 1.43 | Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review. ( Bai, L; Cheng, Z; Dai, G; Han, Z; Liang, P; Liu, F; Tan, S; Yu, J; Yu, X; Zhou, F, 2016) |
"Oesophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-associated death in the world and novel therapeutic alternatives are urgently warranted." | 1.43 | Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway. ( Bai, L; Chen, DL; Chen, LZ; Ju, HQ; Lu, YX; Mo, HY; Sheng, H; Wang, DS; Wang, F; Wu, QN; Xie, D; Xu, RH; Yu, HE; Yun, JP; Zeng, ZL, 2016) |
"Indications for surgery for esophageal cancer often do not include cases with SCLN metastasis because the latter is considered distant metastasis." | 1.42 | Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. ( Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M, 2015) |
"We aimed to identify esophageal squamous cell carcinoma (ESCC) stem-like cells, the epigenetic mechanism and identify novel biomarkers for targeting ESCC CSCs." | 1.42 | Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity. ( Chen, X; Gao, Q; Huang, L; Li, F; Li, J; Li, S; Ping, Y; Wang, D; Wang, L; Yang, L; Yue, D; Zhang, T; Zhang, Y, 2015) |
"However, the esophageal cancer recurred, and subtotal esophagectomy was performed in January 2011." | 1.40 | [A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy]. ( Kigawa, G; Matsubara, T; Matsumiya, A; Mizukami, H; Nemoto, H; Saito, M; Tanaka, J; Tate, G; Umemoto, T, 2014) |
"Esophageal obstruction prior to CCRT, residual tumor according to the first follow-up endoscopy, and poor follow-up computed tomography responses were significantly associated with locoregional failure." | 1.40 | Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation. ( Kim, HW; Kim, JH; Kim, JW; Lee, CG; Lee, IJ; Lee, YC; Park, H; Park, JJ; Youn, YH, 2014) |
"We encountered a case of esophageal squamous cell carcinoma (ESCC) with submucosal tumor (SMT)-like tumor in the cardia of the stomach, formed by direct invasion of the gastric wall." | 1.39 | [A case of esophageal squamous cell carcinoma with submucosal tumor-like tumor due to direct invasion of the gastric wall]. ( Fujiwara, H; Ichikawa, D; Ikoma, H; Komatsu, S; Konishi, H; Kubota, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Nako, Y; Okamoto, K; Otsuji, E; Sakakura, C; Shiozaki, A, 2013) |
"Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2) tyrosine kinase domains." | 1.39 | Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. ( Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 124 (64.92) | 24.3611 |
2020's | 67 (35.08) | 2.80 |
Authors | Studies |
---|---|
Okunaka, M | 1 |
Kotani, D | 1 |
Demachi, K | 1 |
Fujiwara, H | 6 |
Sakashita, S | 1 |
Yoshino, T | 3 |
Fujita, T | 4 |
Kojima, T | 12 |
Hsieh, JC | 1 |
Chiang, PC | 1 |
Hung, TM | 1 |
Chao, YK | 3 |
Kuo, YC | 1 |
Wen, CT | 1 |
Su, PJ | 1 |
Peng, MT | 1 |
Chen, HW | 1 |
Liu, HL | 1 |
Chang, HK | 2 |
Wu, MH | 1 |
Wang, HM | 1 |
Okadome, K | 2 |
Baba, Y | 6 |
Yasuda-Yoshihara, N | 1 |
Nomoto, D | 2 |
Yagi, T | 1 |
Toihata, T | 1 |
Ogawa, K | 4 |
Sawayama, H | 1 |
Ishimoto, T | 3 |
Iwatsuki, M | 2 |
Iwagami, S | 2 |
Miyamoto, Y | 2 |
Yoshida, N | 6 |
Watanabe, M | 13 |
Komohara, Y | 1 |
Baba, H | 5 |
Yoshida, T | 4 |
Nishino, T | 1 |
Goto, M | 1 |
Inoue, S | 1 |
Fujiwara, S | 1 |
Takizawa, H | 1 |
Tangoku, A | 1 |
Uehara, H | 1 |
Bando, Y | 1 |
Mori, Y | 1 |
Kikuchi, O | 1 |
Horimatsu, T | 1 |
Hara, H | 6 |
Hironaka, S | 2 |
Kato, K | 13 |
Tsushima, T | 4 |
Ishihara, R | 1 |
Mukai, K | 1 |
Uozumi, R | 1 |
Tada, H | 1 |
Kasai, H | 1 |
Kawaguchi, A | 1 |
Muto, M | 7 |
Ishikawa, Y | 1 |
Suzuki, M | 1 |
Yamaguchi, H | 1 |
Seto, I | 1 |
Machida, M | 1 |
Takagawa, Y | 1 |
Jingu, K | 1 |
Kikuchi, Y | 1 |
Murakami, M | 2 |
Zhu, Y | 4 |
Liu, K | 2 |
Ding, D | 1 |
Zhou, Y | 2 |
Peng, L | 1 |
Nagata, Y | 3 |
Kageyama, S | 1 |
Ishikawa, T | 3 |
Kokura, S | 1 |
Okayama, T | 2 |
Abe, T | 3 |
Otsuka, K | 3 |
Ariyoshi, T | 1 |
Taniguchi, K | 1 |
Kobayashi, S | 2 |
Shimada, H | 1 |
Yajima, S | 1 |
Suzuki, T | 3 |
Hirano, S | 1 |
Tsuchikawa, T | 1 |
Shichinohe, T | 1 |
Ueda, S | 1 |
Kanetaka, K | 2 |
Yoneda, A | 2 |
Wada, H | 3 |
Doki, Y | 15 |
Yamaue, H | 3 |
Katsuda, M | 3 |
Ohi, M | 1 |
Yasuda, H | 1 |
Kondo, K | 1 |
Kataoka, M | 1 |
Kodera, Y | 3 |
Koike, M | 3 |
Shiraishi, T | 1 |
Miyahara, Y | 1 |
Goshima, N | 1 |
Fukuda, E | 1 |
Yamaguchi, K | 2 |
Sato, E | 1 |
Ikeda, H | 1 |
Yamada, T | 2 |
Osako, M | 1 |
Hirai, K | 1 |
Miyamoto, H | 1 |
Watanabe, T | 1 |
Shiku, H | 1 |
Tang, K | 1 |
Toyozumi, T | 1 |
Murakami, K | 1 |
Sakata, H | 1 |
Kano, M | 1 |
Endo, S | 1 |
Matsumoto, Y | 1 |
Suito, H | 1 |
Takahashi, M | 1 |
Sekino, N | 1 |
Otsuka, R | 1 |
Kinoshita, K | 1 |
Hirasawa, S | 1 |
Hu, J | 1 |
Uesato, M | 1 |
Hayano, K | 1 |
Matsubara, H | 2 |
Nomura, M | 2 |
Kii, T | 3 |
Kawada, J | 1 |
Hirota, M | 1 |
Ohta, T | 1 |
Matsuyama, J | 1 |
Sakai, D | 2 |
Shimokawa, T | 1 |
Kurokawa, Y | 4 |
Kawakami, H | 3 |
Tsujinaka, T | 1 |
Satoh, T | 3 |
Nakajima, M | 3 |
Muroi, H | 2 |
Kikuchi, M | 2 |
Kubo, T | 2 |
Takise, S | 1 |
Ihara, K | 2 |
Nakagawa, M | 2 |
Morita, S | 2 |
Nakamura, T | 8 |
Yamaguchi, S | 2 |
Kojima, K | 2 |
Nishiwaki, N | 1 |
Noma, K | 1 |
Kunitomo, T | 1 |
Hashimoto, M | 1 |
Maeda, N | 1 |
Tanabe, S | 1 |
Sakurama, K | 1 |
Shirakawa, Y | 1 |
Fujiwara, T | 1 |
Matsuda, S | 6 |
Kitagawa, Y | 14 |
Takemura, R | 4 |
Okui, J | 4 |
Okamura, A | 5 |
Kawakubo, H | 7 |
Kakeji, Y | 5 |
Takeuchi, H | 7 |
Sasaki, K | 1 |
Tsuruda, Y | 1 |
Shimonosono, M | 1 |
Noda, M | 1 |
Uchikado, Y | 1 |
Arigami, T | 1 |
Matsushita, D | 1 |
Mori, S | 1 |
Nakajo, A | 1 |
Kurahara, H | 1 |
Ohtsuka, T | 1 |
Ito, R | 1 |
Nakamura, Y | 1 |
Sunakawa, H | 1 |
Hojo, H | 1 |
Nakamura, N | 2 |
Yano, T | 1 |
Daiko, H | 8 |
Akimoto, T | 2 |
Kadono, T | 1 |
Yamamoto, S | 3 |
Hirose, T | 1 |
Ikeda, G | 1 |
Ohara, A | 1 |
Itoyama, M | 1 |
Yokoyama, K | 1 |
Honma, Y | 6 |
Hashimoto, T | 1 |
Sekine, S | 1 |
Ishiyama, K | 2 |
Oguma, J | 3 |
Sugase, T | 1 |
Sugimura, K | 5 |
Kanemura, T | 1 |
Takeoka, T | 1 |
Yamamoto, M | 1 |
Shinno, N | 2 |
Omori, T | 2 |
Fujii, Y | 1 |
Mukai, Y | 1 |
Mikamori, M | 1 |
Hasegawa, S | 2 |
Haraguchi, N | 1 |
Akita, H | 1 |
Nishimura, J | 2 |
Matsuda, C | 1 |
Yasui, M | 2 |
Miyata, H | 8 |
Chan, WL | 1 |
Choi, CW | 1 |
Wong, IY | 1 |
Tsang, TH | 1 |
Lam, AT | 1 |
Tse, RP | 1 |
Chan, KK | 1 |
Wong, C | 1 |
Law, BT | 1 |
Cheung, EE | 1 |
Chan, SY | 1 |
Lam, KO | 1 |
Kwong, D | 1 |
Law, S | 3 |
Lin, CH | 1 |
Chuang, HN | 1 |
Hsiao, TH | 1 |
Kumar, VB | 1 |
Hsu, CH | 2 |
Huang, CY | 1 |
Lee, LW | 1 |
Mao, CL | 1 |
Ko, JL | 1 |
Hsu, CP | 2 |
Mitani, S | 2 |
Shiraishi, O | 8 |
Kanemura, H | 2 |
Suzuki, S | 5 |
Haratani, K | 2 |
Hayashi, H | 2 |
Yonesaka, K | 2 |
Chiba, Y | 2 |
Yasuda, T | 9 |
Nakagawa, K | 5 |
Aoyama, S | 2 |
Motoori, M | 7 |
Yamasaki, M | 10 |
Hirao, M | 4 |
Takeno, A | 4 |
Makino, T | 8 |
Tanaka, K | 5 |
Hamakawa, T | 2 |
Yamashita, K | 6 |
Kimura, Y | 10 |
Fujitani, K | 5 |
Yano, M | 5 |
Kurita, D | 1 |
Kanematsu, K | 1 |
Kubo, K | 1 |
Utsunomiya, D | 1 |
Kato, H | 4 |
Momose, K | 1 |
Hiraki, Y | 1 |
Yasuda, A | 1 |
Shinkai, M | 1 |
Imano, M | 1 |
Miyoshi, S | 1 |
Nishibuchi, I | 2 |
Murakami, Y | 2 |
Katsuta, T | 1 |
Imano, N | 2 |
Hirokawa, J | 1 |
Hamai, Y | 3 |
Emi, M | 3 |
Okada, M | 3 |
Umeki, Y | 1 |
Matsuoka, H | 1 |
Fujita, M | 3 |
Goto, A | 1 |
Serizawa, A | 1 |
Nakamura, K | 5 |
Akimoto, S | 1 |
Nakauchi, M | 1 |
Tanaka, T | 3 |
Shibasaki, S | 1 |
Inaba, K | 2 |
Uyama, I | 1 |
Suda, K | 2 |
Oiki, H | 1 |
Kawabata, R | 1 |
Izutani, Y | 1 |
Kitagawa, A | 1 |
Ushimaru, Y | 1 |
Ohhara, N | 1 |
Miyake, Y | 1 |
Maeda, S | 1 |
Nakata, K | 1 |
Nishikawa, K | 1 |
Miyamoto, A | 1 |
Inoue, N | 1 |
Gao, X | 1 |
Yang, ZH | 1 |
Cheng, YH | 1 |
Chi, CL | 1 |
Yang, TY | 1 |
Chuang, KH | 1 |
Wu, CE | 1 |
van Lanschot, JJ | 1 |
Wen, YW | 2 |
Jiang, H | 2 |
Makelike, K | 1 |
Chen, B | 1 |
Xi, M | 5 |
Li, Q | 4 |
Hu, Y | 4 |
Tsukamoto, Y | 1 |
Kurogi, S | 1 |
Fujishima, H | 1 |
Shibata, T | 2 |
Fumoto, S | 1 |
Nishiki, K | 1 |
Suzuki, K | 1 |
Etoh, T | 1 |
Shiraishi, N | 1 |
Fuchino, T | 1 |
Hirashita, Y | 1 |
Nakada, C | 1 |
Uchida, T | 1 |
Inomata, M | 1 |
Moriyama, M | 1 |
Hijiya, N | 1 |
Shimomura, A | 1 |
Hagiwara, T | 1 |
Yamada, K | 2 |
Yokoi, C | 1 |
Terayama, M | 1 |
Nohara, K | 1 |
Igari, T | 1 |
Kawamura, YI | 1 |
Ogo, T | 1 |
Ishihara, K | 1 |
Nishino, M | 1 |
Inokuch, M | 1 |
Sakurai, U | 1 |
Hagi, T | 1 |
Nishida, N | 1 |
Mori, M | 7 |
Ushigome, H | 1 |
Asukai, K | 1 |
Yanagimoto, Y | 1 |
Takahashi, Y | 1 |
Yamada, D | 1 |
Yamamoto, K | 3 |
Takahashi, H | 2 |
Ohue, M | 1 |
Chen, J | 3 |
Yin, W | 1 |
Yao, H | 1 |
Gu, W | 1 |
Wang, WT | 1 |
Guo, CQ | 1 |
Cui, GH | 1 |
Zhao, S | 1 |
Xiang, X | 1 |
Xiong, R | 1 |
Yu, C | 1 |
Deng, L | 1 |
Bie, J | 1 |
Xiao, D | 1 |
Chen, Z | 3 |
Li, X | 3 |
Feng, G | 2 |
Han, L | 1 |
Cui, D | 1 |
Li, B | 3 |
Xu, WW | 3 |
Lam, AKY | 1 |
Chan, KT | 3 |
Lee, NPY | 1 |
Law, SYK | 1 |
Guan, XY | 3 |
Qin, YR | 3 |
Chan, KW | 3 |
Ma, S | 2 |
Tsao, SW | 3 |
Cheung, ALM | 1 |
Hayashi, M | 2 |
Fukuda, K | 2 |
Mayanagi, S | 2 |
Nakamura, R | 2 |
Hayashida, T | 1 |
Wada, N | 3 |
Nagashima, K | 2 |
Hirano, H | 2 |
Shoji, H | 3 |
Iwasa, S | 4 |
Takashima, A | 3 |
Okita, N | 2 |
Boku, N | 3 |
Murakami, N | 1 |
Ito, Y | 3 |
Itami, J | 2 |
Kanamori, J | 2 |
Mine, S | 1 |
Imamura, Y | 3 |
Asari, T | 1 |
Osumi, H | 1 |
Nakayama, I | 1 |
Ichimura, T | 1 |
Ogura, M | 1 |
Ooki, A | 1 |
Takahari, D | 1 |
Chin, K | 3 |
Dai, H | 1 |
Shao, YW | 1 |
Tong, X | 1 |
Wu, X | 1 |
Pang, J | 1 |
Feng, A | 1 |
Yang, Z | 1 |
Lee, MC | 1 |
Chen, YK | 1 |
Hsu, YJ | 1 |
Lin, BR | 1 |
Randrian, V | 1 |
Adenis, A | 3 |
Desrame, J | 1 |
Barbier, E | 1 |
Di Fiore, F | 1 |
Lièvre, A | 1 |
Dahan, L | 1 |
Laurent-Puig, P | 1 |
Mineur, L | 1 |
Breysacher, G | 1 |
Roquin, G | 1 |
Louafi, S | 1 |
Lopez, A | 1 |
Louvet, C | 1 |
Borg, C | 1 |
Metges, JP | 1 |
Faroux, R | 1 |
Gaba, L | 1 |
Manfredi, S | 1 |
Tougeron, D | 1 |
Connell, C | 1 |
Smyth, EC | 1 |
Ueki, S | 1 |
Fujishima, F | 1 |
Kumagai, T | 1 |
Ishida, H | 2 |
Okamoto, H | 2 |
Takaya, K | 1 |
Sato, C | 2 |
Taniyma, Y | 1 |
Kamei, T | 2 |
Sasano, H | 1 |
Motegi, D | 1 |
Ichikawa, H | 1 |
Kano, Y | 1 |
Hanyu, T | 1 |
Usui, K | 1 |
Sakai, T | 2 |
Hirose, Y | 1 |
Miura, K | 1 |
Nagahashi, M | 1 |
Shimada, Y | 1 |
Sakata, J | 1 |
Kobayashi, T | 1 |
Kameyama, H | 1 |
Wakai, T | 1 |
Hayashi, Y | 3 |
Nakatsuka, R | 1 |
Nishizawa, Y | 1 |
Komatsu, H | 1 |
Miyazaki, S | 1 |
Tomokuni, A | 1 |
Komori, T | 1 |
Iwase, K | 1 |
Nakatani, Y | 1 |
Ushijima, T | 1 |
Chen, L | 1 |
Bi, S | 1 |
Wei, Q | 1 |
Zhao, Z | 3 |
Wang, C | 2 |
Xie, S | 1 |
Cui, Y | 1 |
Yang, D | 1 |
Wang, W | 1 |
Zhang, L | 5 |
Liu, H | 2 |
Guo, W | 1 |
Yao, M | 1 |
Zhang, K | 1 |
Li, W | 1 |
Zhang, Y | 7 |
Guan, F | 1 |
Tsubosa, Y | 6 |
Aoki, K | 1 |
Mizoguchi, Y | 1 |
Kitano, S | 1 |
Yachida, S | 1 |
Shiba, S | 1 |
Saeki, H | 3 |
Jogo, T | 2 |
Kawazoe, T | 1 |
Kamori, T | 1 |
Nakaji, Y | 1 |
Zaitsu, Y | 1 |
Fujiwara, M | 3 |
Iwata, N | 3 |
Egashira, A | 1 |
Nakanoko, T | 1 |
Morita, M | 2 |
Tanaka, Y | 1 |
Nakashima, Y | 3 |
Emi, Y | 1 |
Makiyama, A | 1 |
Oki, E | 3 |
Tokunaga, S | 1 |
Shimokawa, M | 1 |
Zhao, K | 3 |
Hu, S | 1 |
Huang, Y | 1 |
Ma, L | 1 |
Song, Y | 1 |
Li, M | 2 |
Kobayashi, K | 3 |
Maruya, Y | 1 |
Isagawa, Y | 1 |
Yoshimoto, T | 1 |
Migita, K | 1 |
Kawaguchi, Y | 1 |
Kuba, S | 1 |
Okada, S | 1 |
Kosaka, T | 1 |
Inoue, Y | 1 |
Adachi, T | 1 |
Hidaka, M | 1 |
Torashima, Y | 1 |
Ito, S | 1 |
Takatsuki, M | 1 |
Eguchi, S | 1 |
Kanda, M | 2 |
Shimizu, D | 1 |
Tanaka, C | 2 |
Hattori, N | 1 |
Yamada, S | 2 |
Omae, K | 2 |
Nakayama, G | 2 |
Wang, X | 3 |
Geng, X | 1 |
Zhu, L | 1 |
Pucher, PH | 1 |
Rahman, SA | 1 |
Walker, RC | 1 |
Grace, BL | 1 |
Bateman, A | 1 |
Iveson, T | 1 |
Jackson, A | 1 |
Rees, C | 1 |
Byrne, JP | 1 |
Kelly, JJ | 1 |
Noble, F | 1 |
Underwood, TJ | 1 |
Wen, Y | 1 |
Liao, D | 1 |
Miao, J | 1 |
Gui, Y | 1 |
Cai, H | 1 |
Chen, Y | 5 |
Wei, M | 1 |
Jia, Q | 1 |
Tian, H | 1 |
Sun, M | 1 |
Du, X | 1 |
Eguchi, H | 2 |
Katada, C | 3 |
Sugawara, M | 2 |
Fujii, H | 1 |
Nakajima, TE | 1 |
Ando, T | 2 |
Watanabe, A | 1 |
Sakamoto, Y | 3 |
Ishikawa, H | 1 |
Hosokawa, A | 2 |
Hamamoto, Y | 3 |
Tahara, M | 2 |
Koizumi, W | 2 |
Shiozaki, A | 3 |
Kudou, M | 1 |
Konishi, H | 4 |
Shimizu, H | 1 |
Arita, T | 2 |
Kosuga, T | 1 |
Yamamoto, Y | 2 |
Morimura, R | 2 |
Ikoma, H | 3 |
Kuriu, Y | 2 |
Kubota, T | 2 |
Okamoto, K | 3 |
Otsuji, E | 4 |
Dreyfuss, AD | 1 |
Barsky, AR | 1 |
Wileyto, EP | 1 |
Eads, JR | 1 |
Kucharczuk, JC | 1 |
Williams, NN | 1 |
Karasic, TB | 1 |
Metz, JM | 1 |
Ben-Josef, E | 1 |
Plastaras, JP | 1 |
Wojcieszynski, AP | 1 |
Zhu, H | 2 |
Rivin Del Campo, E | 1 |
Ye, J | 2 |
Simone, CB | 1 |
Zhu, Z | 2 |
Zhao, W | 2 |
Amini, A | 1 |
Zhou, J | 2 |
Wu, C | 1 |
Tang, H | 1 |
Fan, M | 2 |
Li, L | 3 |
Lin, Q | 2 |
Xia, Y | 1 |
Li, Y | 4 |
Li, J | 4 |
Mo, M | 1 |
Jia, H | 1 |
Lu, S | 1 |
Wang, J | 4 |
Nie, Y | 1 |
Wu, S | 2 |
Hamaji, M | 1 |
Haque, W | 1 |
Jeong, BK | 1 |
Shridhar, R | 1 |
Zhang, Z | 1 |
Zhu, J | 1 |
Zhang, X | 1 |
Wen, B | 1 |
Lu, Y | 2 |
Xu, W | 1 |
Marguet, S | 1 |
Delaine-Clisant, S | 1 |
Penel, N | 1 |
Bonastre, J | 1 |
Matsuura, N | 1 |
Saito, T | 1 |
Takahashi, T | 3 |
Nakajima, K | 3 |
Nakagawa, H | 1 |
Shim, YM | 2 |
Yun, J | 1 |
Im, YH | 1 |
Lee, G | 1 |
Kang, D | 1 |
Cho, J | 1 |
Kim, K | 1 |
Park, SI | 1 |
Na, KJ | 1 |
Kim, SB | 1 |
Zo, JI | 2 |
Nakaya, S | 1 |
Ogawa, R | 1 |
Hayakawa, S | 1 |
Fujihata, S | 1 |
Okubo, T | 1 |
Sagawa, H | 1 |
Matsuo, Y | 1 |
Takiguchi, S | 3 |
Wang, Z | 3 |
Hu, M | 1 |
Wu, J | 1 |
Fong, WP | 1 |
Ren, C | 1 |
Wang, D | 2 |
Tan, Q | 1 |
Yang, H | 5 |
Li, N | 1 |
Li, D | 1 |
Zheng, X | 2 |
Lian, J | 1 |
Li, S | 2 |
Cui, H | 1 |
Sang, L | 1 |
Wang, Y | 5 |
Yu, JJ | 1 |
Lu, T | 1 |
Zhang, C | 1 |
Ma, Q | 1 |
Shi, Y | 1 |
Wang, M | 1 |
Ge, J | 1 |
Anvari, K | 1 |
Sima, HR | 1 |
Seilanian Toussi, M | 1 |
Anvari, A | 1 |
Shahidsales, S | 1 |
Memar, B | 1 |
Aledavoud, SA | 1 |
Forghani, MN | 1 |
Abdollahi, A | 1 |
Ghaffarzadegan, K | 1 |
Liu, J | 1 |
Zhang, W | 3 |
Deng, W | 1 |
Yue, J | 1 |
Zhang, P | 4 |
Yang, YD | 1 |
Liu, SL | 3 |
Fu, JH | 2 |
Liu, MZ | 4 |
Yamashita, H | 2 |
Seto, Y | 1 |
Takenaka, R | 2 |
Okuma, K | 2 |
Kiritooshi, T | 1 |
Mori, K | 3 |
Fukuda, T | 1 |
Kaminishi, M | 1 |
Abe, O | 1 |
Nakajima, Y | 2 |
Kawada, K | 2 |
Tokairin, Y | 2 |
Hoshino, A | 1 |
Okada, T | 2 |
Kawano, T | 4 |
Akiyama, Y | 2 |
Iwaya, T | 2 |
Endo, F | 2 |
Chiba, T | 2 |
Takahara, T | 2 |
Nitta, H | 2 |
Koeda, K | 2 |
Mizuno, M | 2 |
Sasaki, A | 2 |
Okuno, T | 5 |
Wakabayashi, M | 1 |
Shinoda, M | 4 |
Katayama, H | 3 |
Igaki, H | 3 |
Okabe, H | 2 |
Kosugi, S | 2 |
Toh, Y | 2 |
Fukuda, H | 4 |
Ishikura, S | 3 |
Ando, N | 5 |
Mynhardt, C | 1 |
Damelin, LH | 1 |
Jivan, R | 1 |
Peres, J | 1 |
Prince, S | 1 |
Veale, RB | 1 |
Mavri-Damelin, D | 1 |
Bascoul-Mollevi, C | 1 |
Gourgou, S | 1 |
Galais, MP | 1 |
Raoul, JL | 1 |
Bouché, O | 1 |
Douillard, JY | 1 |
Etienne, PL | 1 |
Juzyna, B | 1 |
Bedenne, L | 1 |
Conroy, T | 1 |
Kumabe, A | 2 |
Zenda, S | 2 |
Motegi, A | 1 |
Onozawa, M | 1 |
Shigematsu, N | 2 |
Fujimoto, Y | 2 |
Sasaki, S | 1 |
Hirose, K | 1 |
Edahiro, K | 1 |
Korehisa, S | 1 |
Taniguchi, D | 1 |
Kudou, K | 1 |
Nakaji, YU | 1 |
Nakanishi, R | 1 |
Ando, K | 1 |
Oda, Y | 1 |
Maehara, Y | 2 |
Guo, L | 1 |
Cheng, X | 1 |
Ke, S | 1 |
Shi, W | 1 |
Miyazaki, Y | 2 |
Yu, FJ | 1 |
Shih, HY | 1 |
Wu, CY | 1 |
Chuang, YS | 1 |
Lee, JY | 1 |
Li, HP | 1 |
Fang, PT | 1 |
Tsai, DL | 1 |
Chou, SH | 1 |
Wu, IC | 1 |
Fukada, J | 1 |
Kota, R | 1 |
Koike, N | 1 |
Shiraishi, Y | 1 |
Seki, S | 1 |
Yoshida, K | 2 |
Muroya, T | 2 |
Wajima, N | 2 |
Yachi, T | 1 |
Akaishi, T | 1 |
Umetsu, S | 2 |
Wakasa, Y | 2 |
Sato, K | 1 |
Mitsuhashi, Y | 1 |
Umemura, K | 1 |
Tsuruta, S | 1 |
Hakamada, K | 2 |
Hsieh, HY | 1 |
Yeh, HL | 1 |
Chuang, CY | 1 |
Lin, JF | 1 |
Chang, CF | 1 |
Fujiwara, Y | 1 |
Lee, S | 1 |
Kishida, S | 1 |
Hashiba, R | 1 |
Gyobu, K | 1 |
Naka, R | 1 |
Nishiyama, M | 2 |
Ihara, T | 1 |
Takemura, M | 1 |
Osugi, H | 1 |
Kawakami, T | 1 |
Ogawa, H | 2 |
Shirasu, H | 1 |
Kito, Y | 1 |
Yoshida, Y | 1 |
Hamauchi, S | 2 |
Todaka, A | 1 |
Machida, N | 1 |
Yokota, T | 5 |
Yamazaki, K | 1 |
Fukutomi, A | 1 |
Onozawa, Y | 2 |
Yasui, H | 2 |
Doosti-Irani, A | 1 |
Holakouie-Naieni, K | 1 |
Rahimi-Foroushani, A | 1 |
Mansournia, MA | 1 |
Haddad, P | 1 |
Hihara, J | 2 |
Takeuchi, Y | 1 |
Takahashi, I | 1 |
Kimura, T | 2 |
Taniyama, Y | 1 |
Sakurai, T | 1 |
Heishi, T | 1 |
Teshima, J | 1 |
Maruyama, S | 1 |
Ito, K | 1 |
Onodera, Y | 1 |
Konno-Kumagai, T | 1 |
Gombodorj, N | 1 |
Yokobori, T | 2 |
Tanaka, N | 2 |
Kuriyama, K | 1 |
Kumakura, Y | 1 |
Sakai, M | 2 |
Sohda, M | 2 |
Baatar, S | 1 |
Miyazaki, T | 2 |
Shirabe, K | 1 |
Kuwano, H | 2 |
Chen, YH | 1 |
Lu, HI | 1 |
Lo, CM | 1 |
Wang, YM | 1 |
Chou, SY | 1 |
Hsiao, CC | 1 |
Huang, CC | 1 |
Shih, LH | 1 |
Chen, SW | 1 |
Li, SH | 1 |
Abbaszadegan, MR | 1 |
Taghehchian, N | 1 |
Aarabi, A | 1 |
Moghbeli, M | 1 |
Kawamoto, T | 1 |
Nihei, K | 1 |
Doki, N | 1 |
Najima, Y | 1 |
Kaito, S | 1 |
Karasawa, K | 1 |
Ai, D | 1 |
Liu, Q | 3 |
Zhang, J | 1 |
Deng, J | 1 |
Ren, W | 1 |
Wei, S | 1 |
Luo, H | 1 |
Cao, J | 1 |
Huang, G | 1 |
Wu, K | 1 |
Fan, J | 1 |
Badakhshi, H | 1 |
Huang, TC | 1 |
Lin, CC | 1 |
Wu, YC | 1 |
Chia-Hsien Cheng, J | 1 |
Lee, JM | 2 |
Wang, HP | 1 |
Huang, PM | 2 |
Hsu, FM | 1 |
Yeh, KH | 1 |
Cheng, AL | 1 |
Tzen, KY | 1 |
Huang, C | 1 |
Yuan, Y | 1 |
Liu, M | 2 |
Pendleton, EG | 1 |
Jamasbi, RJ | 1 |
Geusz, ME | 1 |
Iijima, H | 2 |
Isohashi, F | 2 |
Tsujii, Y | 1 |
Fujinaga, T | 1 |
Nagai, K | 1 |
Yoshii, S | 1 |
Sakatani, A | 1 |
Hiyama, S | 1 |
Shinzaki, S | 2 |
Takehara, T | 2 |
Takeuchi, M | 1 |
Irino, T | 1 |
Zhou, S | 1 |
Liu, S | 2 |
Zhao, L | 4 |
Chen, Q | 1 |
Hou, J | 1 |
Wu, Z | 1 |
Zhao, J | 1 |
Nagai, Y | 1 |
Harada, K | 2 |
Imai, K | 1 |
Karashima, R | 1 |
Koga, Y | 1 |
Yoshida, J | 1 |
Doi, T | 2 |
Ota, T | 1 |
Sakamoto, N | 2 |
Inoue, K | 1 |
Dohi, O | 1 |
Kamada, K | 1 |
Uchiyama, K | 1 |
Takagi, T | 1 |
Naito, Y | 1 |
Itoh, Y | 1 |
Ito, T | 1 |
Nikai, H | 1 |
Baba, S | 1 |
Hayakawa, Y | 1 |
Matsuoka, M | 1 |
Nozaka, T | 1 |
Misumi, Y | 1 |
Matsumoto, T | 1 |
Miura, N | 1 |
Furumoto, Y | 1 |
Asano, T | 1 |
Horiuchi, T | 1 |
Fujiki, K | 1 |
Fukuoka, E | 1 |
Sawada, R | 1 |
Sugita, Y | 1 |
Arimoto, A | 1 |
Takiguchi, G | 1 |
Matsuda, T | 1 |
Oshikiri, T | 1 |
Ura, T | 2 |
Kojima, Y | 1 |
Akutsu, Y | 2 |
Matsushita, H | 1 |
Kawakami, K | 1 |
Makiuchi, T | 1 |
Nagumo, R | 1 |
Hou, W | 1 |
Qin, X | 1 |
Zhu, X | 1 |
Fei, M | 1 |
Liu, P | 1 |
Liu, L | 2 |
Moon, H | 1 |
Greshock, J | 1 |
Bachman, KE | 1 |
Ye, BC | 1 |
Wang, H | 2 |
Zang, CY | 1 |
Ichikawa, D | 2 |
Shoda, K | 1 |
Komatsu, S | 2 |
Ochiai, T | 1 |
Inoue, J | 1 |
Inazawa, J | 1 |
Zhao, Y | 1 |
Bao, Q | 1 |
Schwarz, B | 1 |
Mysliwietz, J | 1 |
Ellwart, J | 1 |
Renner, A | 1 |
Hirner, H | 1 |
Niess, H | 1 |
Camaj, P | 1 |
Angele, M | 1 |
Gros, S | 1 |
Izbicki, J | 1 |
Jauch, KW | 1 |
Nelson, PJ | 1 |
Bruns, CJ | 1 |
Sakogawa, K | 1 |
Aoki, Y | 1 |
Misumi, K | 1 |
Shi, L | 1 |
Kono, K | 1 |
Horikoshi, Y | 1 |
Sun, J | 1 |
Ikura, T | 1 |
Tashiro, S | 1 |
Lin, W | 2 |
Lin, S | 1 |
Lin, Y | 1 |
Omatsu, H | 3 |
Kuwahara, A | 4 |
Yamamori, M | 4 |
Miki, I | 4 |
Tamura, T | 4 |
Nishiguchi, K | 4 |
Okamura, N | 1 |
Azuma, T | 3 |
Hirano, T | 1 |
Ozawa, K | 1 |
Hirai, M | 3 |
Sunpaweravong, S | 1 |
Puttawibul, P | 1 |
Ruangsin, S | 1 |
Laohawiriyakamol, S | 1 |
Sunpaweravong, P | 1 |
Sangthawan, D | 1 |
Pradutkanchana, J | 1 |
Raungkhajorn, P | 1 |
Geater, A | 1 |
Kajiura, S | 1 |
Yoshita, H | 1 |
Ueda, Y | 1 |
Ueda, A | 1 |
Mihara, H | 1 |
Fujinami, H | 1 |
Nishikawa, J | 1 |
Minemura, M | 1 |
Sugiyama, T | 1 |
Nako, Y | 1 |
Murayama, Y | 1 |
Nakanishi, M | 1 |
Sakakura, C | 1 |
Yusup, G | 1 |
Mutallip, M | 1 |
Qin, W | 1 |
Hu, X | 1 |
Komatsu-Akimoto, A | 1 |
Hoshino, I | 1 |
Hanari, N | 1 |
Akanuma, N | 1 |
Isozaki, Y | 1 |
Minegaki, T | 1 |
Sakaeda, T | 3 |
Furutani, A | 1 |
Sowa, Y | 1 |
Blazeby, JM | 1 |
Strong, S | 1 |
Donovan, JL | 1 |
Wilson, C | 1 |
Hollingworth, W | 1 |
Crosby, T | 1 |
Nicklin, J | 1 |
Falk, SJ | 1 |
Barham, CP | 1 |
Hollowood, AD | 1 |
Streets, CG | 1 |
Titcomb, D | 1 |
Krysztopik, R | 1 |
Griffin, SM | 1 |
Brookes, ST | 1 |
Ishikawa, K | 1 |
Nakamatsu, K | 1 |
Nishimura, Y | 1 |
O'Callaghan, C | 1 |
Fanning, LJ | 1 |
Barry, OP | 1 |
Nemoto, H | 1 |
Tate, G | 1 |
Umemoto, T | 1 |
Matsubara, T | 1 |
Mizukami, H | 1 |
Saito, M | 1 |
Kigawa, G | 1 |
Matsumiya, A | 1 |
Tanaka, J | 1 |
Shen, JX | 1 |
Li, QQ | 2 |
He, LR | 1 |
Ma, W | 1 |
Zhang, T | 3 |
Pan, J | 1 |
Shi, N | 1 |
Fan, Q | 1 |
Wang, L | 2 |
Lu, SH | 1 |
Lindner, K | 1 |
Borchardt, C | 1 |
Schöpp, M | 1 |
Bürgers, A | 1 |
Stock, C | 1 |
Hussey, DJ | 2 |
Haier, J | 2 |
Hummel, R | 2 |
Nishida, T | 1 |
Tsujii, M | 1 |
Tsutsui, S | 1 |
Kato, M | 1 |
Liu, Y | 1 |
Zheng, K | 1 |
Yan, H | 1 |
Chen, W | 1 |
Wang, S | 1 |
Yue, D | 1 |
Chen, X | 1 |
Ping, Y | 1 |
Gao, Q | 1 |
Li, F | 1 |
Yang, L | 1 |
Huang, L | 1 |
Sie, C | 1 |
Watson, DI | 1 |
Wang, T | 2 |
Ansar, A | 1 |
Michael, MZ | 1 |
Van der Hoek, M | 1 |
Omori, M | 1 |
Kobayashi, R | 1 |
Ohtomo, K | 1 |
Ordu, AD | 1 |
Nieder, C | 1 |
Geinitz, H | 1 |
Scherer, V | 1 |
Kup, PG | 1 |
Schuster, T | 1 |
Combs, SE | 1 |
Fakhrian, K | 1 |
Kim, HW | 1 |
Kim, JH | 1 |
Lee, IJ | 1 |
Kim, JW | 1 |
Lee, YC | 1 |
Lee, CG | 1 |
Park, JJ | 1 |
Youn, YH | 1 |
Park, H | 1 |
Yu, W | 1 |
Cai, XW | 1 |
Zhu, ZF | 1 |
Feng, W | 1 |
Zhang, Q | 2 |
Zhang, YJ | 1 |
Yao, ZF | 1 |
Fu, XL | 1 |
Zhang, WW | 1 |
Zhu, YJ | 1 |
Wang, QX | 1 |
Wang, XH | 1 |
Xiao, WW | 1 |
Hu, YH | 1 |
Minashi, K | 1 |
Yamashita, M | 1 |
Takenaka, HY | 1 |
Ji, YH | 1 |
Yang, XY | 1 |
Wu, JQ | 1 |
Huo, XQ | 1 |
Li, WW | 1 |
Li, GJ | 1 |
Mu, YL | 1 |
Lu, P | 1 |
Yang, JS | 1 |
Qiu, MQ | 1 |
Li, QL | 1 |
Mizusawa, J | 2 |
Tamura, S | 2 |
Taniguchi, H | 2 |
Katsura, Y | 1 |
Ohmura, Y | 1 |
Kagawa, Y | 1 |
Sakisaka, H | 1 |
Takeda, Y | 1 |
Kato, T | 2 |
Chiu, CH | 1 |
Chen, WH | 1 |
Yeh, CJ | 1 |
Tseng, CK | 1 |
Liu, YH | 1 |
Luo, LL | 1 |
Tian, J | 1 |
Shang, M | 1 |
Shi, SB | 1 |
Han, Y | 1 |
Xu, J | 1 |
Niwa, Y | 2 |
Oya, H | 1 |
Nishio, N | 1 |
Hiramatsu, M | 1 |
Kobayashi, D | 1 |
Fujii, T | 1 |
Sugimoto, H | 1 |
Nomoto, S | 1 |
Najafzadeh, N | 1 |
Mazani, M | 1 |
Abbasi, A | 1 |
Farassati, F | 1 |
Amani, M | 1 |
Okada, N | 1 |
Fujii, S | 2 |
Hayashi, R | 1 |
Lee, NP | 2 |
Tam, PY | 1 |
Li, YY | 1 |
Yuen, HF | 1 |
He, QY | 1 |
Cheung, AL | 2 |
Izumi, D | 1 |
Shiraishi, S | 1 |
Kosumi, K | 1 |
Tokunaga, R | 1 |
Taki, K | 1 |
Higashi, T | 1 |
Miyata, T | 1 |
Ida, S | 1 |
Yamashita, Y | 1 |
Ojima, T | 2 |
Nakamori, M | 2 |
Nakamura, M | 2 |
Hayata, K | 2 |
Matsumura, S | 1 |
Iwahashi, M | 2 |
Akasaka, H | 1 |
Ichinohe, D | 1 |
Kitadani, J | 1 |
Tabata, H | 1 |
Takeuchi, A | 1 |
Katada, N | 2 |
Moriya, H | 2 |
Hosoda, K | 2 |
Mieno, H | 2 |
Hoshi, K | 1 |
Honjo, H | 1 |
Hara, K | 1 |
Ozawa, D | 1 |
Koca, D | 1 |
Ozdemir, O | 1 |
Demir, D | 1 |
Akdeniz, H | 1 |
Kurt, M | 1 |
Sato, H | 1 |
Takebayashi, K | 1 |
Kawamorita, K | 1 |
Niihara, M | 1 |
Oze, I | 1 |
Kodaira, T | 1 |
Komori, A | 1 |
Narita, Y | 1 |
Masuishi, T | 1 |
Kadowaki, S | 1 |
Andoh, M | 1 |
Tachibana, H | 1 |
Uemura, N | 1 |
Tajika, M | 1 |
Muro, K | 1 |
Miyawaki, Y | 1 |
Tryakin, A | 1 |
Pokataev, I | 1 |
Kononets, P | 1 |
Fedyanin, M | 1 |
Bokhyan, V | 1 |
Malikhova, O | 1 |
Minin, K | 1 |
Shogenov, M | 1 |
Stilidi, I | 1 |
Vybarava, A | 1 |
Davydov, M | 1 |
Tjulandin, S | 1 |
Zhou, F | 1 |
Yu, X | 1 |
Liang, P | 1 |
Cheng, Z | 1 |
Han, Z | 1 |
Yu, J | 1 |
Liu, F | 1 |
Tan, S | 1 |
Dai, G | 1 |
Bai, L | 2 |
Hatogai, K | 1 |
Kadota, T | 1 |
Takiguchi, Y | 1 |
Ohtsu, A | 2 |
Satake, H | 1 |
Mochizuki, S | 1 |
Kiyota, N | 1 |
Bando, H | 1 |
Yamazaki, T | 1 |
Hu, G | 1 |
Tang, N | 1 |
Guo, J | 1 |
Han, X | 1 |
Hiyoshi, Y | 1 |
Kurashige, J | 1 |
Gemici, C | 1 |
Yaprak, G | 1 |
Batirel, HF | 1 |
Ilhan, M | 1 |
Mayadagli, A | 1 |
Li, CY | 1 |
Chu, PY | 1 |
Chen, PM | 1 |
Lin, MW | 1 |
Kuo, SW | 1 |
Lu, YX | 1 |
Chen, DL | 1 |
Wang, DS | 1 |
Chen, LZ | 1 |
Mo, HY | 1 |
Sheng, H | 1 |
Wu, QN | 1 |
Yu, HE | 1 |
Xie, D | 1 |
Yun, JP | 1 |
Zeng, ZL | 1 |
Wang, F | 1 |
Ju, HQ | 1 |
Xu, RH | 1 |
Lim, SH | 1 |
Park, SH | 1 |
Kim, HK | 1 |
Choi, YS | 1 |
Ahn, MJ | 1 |
Park, K | 1 |
Sun, JM | 1 |
Shigaki, H | 1 |
Komori, S | 1 |
Kawai, T | 1 |
Kochi, M | 1 |
Fujii, M | 1 |
Song, K | 1 |
Hagiwara, K | 1 |
Tamegai, H | 1 |
Matsuno, Y | 1 |
Takayama, Y | 1 |
Suda, H | 1 |
Takayama, T | 1 |
Zhu, ZQ | 1 |
Zhu, ZA | 1 |
Cai, HX | 1 |
Zhao, T | 1 |
Chen, H | 1 |
Mizuno, S | 1 |
Manabe, Y | 1 |
Chen, MY | 1 |
Luo, JC | 1 |
Wei, L | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Ad[NCT03189719] | Phase 3 | 749 participants (Actual) | Interventional | 2017-07-25 | Completed | ||
Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA A Multi-centre, Randomized, Non-comparative Phase II Study[NCT03719924] | Phase 2 | 106 participants (Actual) | Interventional | 2019-03-07 | Active, not recruiting | ||
A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma[NCT05213312] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma FRONTiER Trial[NCT03914443] | Phase 1 | 36 participants (Anticipated) | Interventional | 2019-05-07 | Active, not recruiting | ||
Prospective, Randomized, Multicenter, Phase II Noninferiority Study of S-1 Concurrent Intensity-modulated Radiation Therapy (IMRT) Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma[NCT02913066] | Phase 2 | 88 participants (Anticipated) | Interventional | 2016-09-30 | Recruiting | ||
Paclitaxel In Combination With Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial[NCT02976909] | Phase 2 | 46 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480] | Phase 2 | 63 participants (Actual) | Interventional | 2020-02-01 | Completed | ||
A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial[NCT02459457] | Phase 3 | 321 participants (Actual) | Interventional | 2015-07-01 | Completed | ||
Dose Escalation Using a Simultaneous Integrated Boost Technique Based on 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer: a Phase I/II Trial[NCT01843049] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
Measurement of the Distance Between the Corresponding Anatomical Landmarks in the Thoracic Cavity and the Incisors[NCT03720405] | 520 participants (Anticipated) | Observational [Patient Registry] | 2018-07-31 | Recruiting | |||
Sichuan Cancer Hospital & Institute[NCT05604950] | 2 participants (Actual) | Observational [Patient Registry] | 2009-01-01 | Completed | |||
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)[NCT04138212] | Phase 3 | 456 participants (Anticipated) | Interventional | 2019-10-22 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who were PD-L1 CPS ≥10." (NCT03189719)
Timeframe: Baseline, Week 18
Intervention | Score on a Scale (Least Squares Mean) |
---|---|
Pembrolizumab + SOC | -1.73 |
Placebo + SOC | 0.04 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who had ESCC." (NCT03189719)
Timeframe: Baseline, Week 18
Intervention | Score on a Scale (Least Squares Mean) |
---|---|
Pembrolizumab + SOC | -2.00 |
Placebo + SOC | -1.94 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants who had ESCC and who were PD-L1 CPS ≥10." (NCT03189719)
Timeframe: Baseline, Week 18
Intervention | Score on a Scale (Least Squares Mean) |
---|---|
Pembrolizumab + SOC | -2.36 |
Placebo + SOC | -0.40 |
"The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients. Participant responses to the Global Health Status (GHS) question How would you rate your overall health during the past week? (Item 29) and the Quality of Life (QoL) question How would you rate your overall quality of life during the past week? (Item 30) were scored on a 7-point scale (1=Very Poor to 7=Excellent). Using linear transformation, raw scores were standardized so that scores ranged from 0 to 100, with a higher score indicating a better overall outcome. Per protocol, change from baseline to Week 18 in the GHS/QoL combined score was reported by treatment arm as a pre-specified secondary analysis for all participants." (NCT03189719)
Timeframe: Baseline, Week 18
Intervention | Score on a Scale (Least Squares Mean) |
---|---|
Pembrolizumab + SOC | -1.74 |
Placebo + SOC | -1.64 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Months (Median) |
---|---|
Pembrolizumab + SOC | 10.4 |
Placebo + SOC | 5.6 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Months (Median) |
---|---|
Pembrolizumab + SOC | 9.1 |
Placebo + SOC | 6.1 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR, and who had ESCC and were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Months (Median) |
---|---|
Pembrolizumab + SOC | 10.4 |
Placebo + SOC | 4.4 |
For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by the investigator, DOR was defined as the time from first documented evidence of confirmed CR or PR until PD or death due to any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Per protocol, DOR is reported here for all participants of the ITT population (all randomized) who had CR or PR. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Months (Median) |
---|---|
Pembrolizumab + SOC | 8.3 |
Placebo + SOC | 6.0 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm. (NCT03189719)
Timeframe: Up to approximately 27 months
Intervention | Participants (Count of Participants) |
---|---|
Pembrolizumab + SOC | 90 |
Placebo + SOC | 74 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm. (NCT03189719)
Timeframe: Up to approximately 28 months
Intervention | Participants (Count of Participants) |
---|---|
Pembrolizumab + SOC | 370 |
Placebo + SOC | 368 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized). (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Percentage of Participants (Number) |
---|---|
Pembrolizumab + SOC | 45.0 |
Placebo + SOC | 29.3 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Percentage of Participants (Number) |
---|---|
Pembrolizumab + SOC | 51.1 |
Placebo + SOC | 26.9 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Percentage of Participants (Number) |
---|---|
Pembrolizumab + SOC | 43.8 |
Placebo + SOC | 31.0 |
ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. as assessed by the investigator. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, the percentage of participants who experienced CR or PR is reported here as the ORR for all participants of the ITT population (all randomized) who had ESCC and who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Percentage of Participants (Number) |
---|---|
Pembrolizumab + SOC | 51.0 |
Placebo + SOC | 28.0 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized). (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Months (Median) |
---|---|
Pembrolizumab + SOC | 12.4 |
Placebo + SOC | 9.8 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Months (Median) |
---|---|
Pembrolizumab + SOC | 13.5 |
Placebo + SOC | 9.4 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Months (Median) |
---|---|
Pembrolizumab + SOC | 12.6 |
Placebo + SOC | 9.8 |
Overall survival was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Per protocol, OS is reported here for all participants of the Intent-To-Treat (ITT) population (all randomized) who had ESCC and who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Months (Median) |
---|---|
Pembrolizumab + SOC | 13.9 |
Placebo + SOC | 8.8 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Months (Median) |
---|---|
Pembrolizumab + SOC | 6.3 |
Placebo + SOC | 5.8 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who were PD-L1 CPS ≥10. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Months (Median) |
---|---|
Pembrolizumab + SOC | 7.5 |
Placebo + SOC | 5.5 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The sponsor allowed a maximum of 10 target lesions in total and 5 per organ on this study. Per protocol, PFS is reported here for all participants of the ITT population (all randomized) who had ESCC. (NCT03189719)
Timeframe: Up to approximately 34 months (through Primary Analysis cut-off date of 02-Jul-2020)
Intervention | Months (Median) |
---|---|
Pembrolizumab + SOC | 6.3 |
Placebo + SOC | 5.8 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants who were PD-L1 CPS≥10 in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
Intervention | Score on a Scale (Least Squares Mean) | ||
---|---|---|---|
Dysphagia subscale | Pain subscale | Reflux subscale | |
Pembrolizumab + SOC | -7.18 | -3.51 | -0.52 |
Placebo + SOC | 1.02 | 0.07 | 4.25 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants with ESCC in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
Intervention | Score on a Scale (Least Squares Mean) | ||
---|---|---|---|
Dysphagia subscale | Pain subscale | Reflux subscale | |
Pembrolizumab + SOC | -1.18 | -4.03 | -0.40 |
Placebo + SOC | 3.32 | -2.33 | 1.09 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores representing a higher (worse) level of symptoms. Change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for participants with ESCC who were PD-L1 CPS≥10 in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
Intervention | Score on a Scale (Least Squares Mean) | ||
---|---|---|---|
Dysphagia subscale | Pain subscale | Reflux subscale | |
Pembrolizumab + SOC | -5.11 | -2.55 | -0.16 |
Placebo + SOC | 3.57 | -0.42 | 4.94 |
"The EORTC QLQ-OES18 is a disease-specific questionnaire developed and validated to address measurements specific to esophageal cancer and contains 18 items assessing symptoms of dysphagia, pain, reflux symptoms, eating restrictions, anxiety, dry mouth, taste, body image, and hair loss. For the purposes of this study, the Dysphagia subscale (three items), Pain subscale (three items), and Reflux subscale (two items) were evaluated. All subscale items were scored using a four-point Likert scale with the following response choices: 1=not at all, 2=a little, 3=quite a bit, 4=very much. Raw scores for the subscales were standardized into a range of 0 to 100 by linear transformation, with higher symptom scores represent a higher (worse) level of symptoms. Per protocol, change from baseline to Week 18 in the Dysphagia, Pain, and Reflux subscales was reported for all participants in each treatment arm. Negative changes from baseline indicate a decrease in symptom severity." (NCT03189719)
Timeframe: Baseline, Week 18
Intervention | Score on a Scale (Least Squares Mean) | ||
---|---|---|---|
Dysphagia subscale | Pain subscale | Reflux subscale | |
Pembrolizumab + SOC | -3.18 | -4.78 | -0.22 |
Placebo + SOC | 2.36 | -1.85 | 0.71 |
6 reviews available for fluorouracil and Esophageal Squamous Cell Carcinoma
Article | Year |
---|---|
Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal | 2023 |
Chemoradiotherapy for Solitary Skeletal Muscle Metastasis from Oesophageal Cancer: Case Report and Brief Literature Review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Squamous | 2017 |
A network meta-analysis of the treatments for esophageal squamous cell carcinoma in terms of survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Carcinoma, Squamous Cell | 2018 |
Treatment options for esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2016 |
Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2017 |
39 trials available for fluorouracil and Esophageal Squamous Cell Carcinoma
Article | Year |
---|---|
Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Japan; Neoplasm Recu | 2022 |
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
Topics: Antibodies, Neoplasm; Antigens, Neoplasm; Cancer Vaccines; Cisplatin; Esophageal Neoplasms; Esophage | 2022 |
A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell | 2022 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial.
Topics: Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; F | 2023 |
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progress | 2020 |
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as | 2020 |
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as | 2020 |
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as | 2020 |
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as | 2020 |
An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Comb | 2020 |
Single-Agent Versus Double-Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2020 |
Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients With Clinical T4b Esophageal Cancer: Short-term Result
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2021 |
Clinical safety and efficacy of neoadjuvant combination chemotherapy of tranilast in advanced esophageal squamous cell carcinoma: Phase I/II study (TNAC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dose | 2020 |
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Topics: Aged; Chemoradiotherapy; China; Cisplatin; Confidence Intervals; Dose Fractionation, Radiation; Drug | 2021 |
Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analys | 2021 |
The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Dis | 2022 |
Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial.
Topics: Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Induction | 2022 |
Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Squamous | 2017 |
Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, | 2017 |
Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; China; Cisplatin; Cl | 2018 |
Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2019 |
A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esoph | 2020 |
Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2013 |
Randomized study of antiinflammatory and immune-modulatory effects of enteral immunonutrition during concurrent chemoradiotherapy for esophageal cancer.
Topics: Adult; Aged; Arginine; C-Reactive Protein; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; E | 2014 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2014 |
Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18)FDG-PET/CT for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2015 |
Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2015 |
Comparison of efficacy and toxicity profiles between paclitaxel/lobapoatin- and cisplatin/5-fluorouracil-based concurrent chemoradiotherapy of advanced inoperable oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2015 |
Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; C | 2015 |
Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2016 |
Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2016 |
Preoperative chemotherapy in patients with resectable esophageal carcinoma: a single center Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2016 |
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2017 |
A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2017 |
Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2012 |
[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2012 |
146 other studies available for fluorouracil and Esophageal Squamous Cell Carcinoma
Article | Year |
---|---|
Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2022 |
Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence.
Topics: Adult; Aged; Aged, 80 and over; Carboplatin; Chemoradiotherapy; Cisplatin; Esophageal Squamous Cell | 2021 |
PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Esophageal Neoplasms; Esophageal Squa | 2022 |
ypN0 in Patients With Definitive cN-positive Status After Preoperative Treatment Is a Prognostic Factor in Esophageal Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant | 2022 |
Long-term survival after definitive proton beam therapy for oligorecurrent esophageal squamous cell carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2022 |
Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Ci | 2022 |
HIF-1α stimulates the progression of oesophageal squamous cell carcinoma by activating the Wnt/β-catenin signalling pathway.
Topics: beta Catenin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Esophageal Neoplasms; | 2022 |
Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans | 2022 |
Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2022 |
Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Es | 2023 |
Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2022 |
Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinom | 2022 |
Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neopl | 2023 |
Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2022 |
AGR2 expression as a predictive biomarker for therapy response in esophageal squamous cell carcinoma.
Topics: Biomarkers; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagecto | 2022 |
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor | 2023 |
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor | 2023 |
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor | 2023 |
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Topics: B7-H1 Antigen; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluor | 2023 |
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluor | 2023 |
Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esop | 2023 |
Long-term results of chemoradiotherapy with elective nodal irradiation for resectable locally advanced esophageal cancer in three-dimensional planning system.
Topics: Aged; Aged, 80 and over; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma | 2023 |
Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers.
Topics: Aged; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; East A | 2023 |
Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
[A Case Report of Stage Ⅳb Thoracic Esophageal Cancer Responding to Multidisciplinary Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Sq | 2022 |
Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage | 2023 |
Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cost-Effectiveness Ana | 2023 |
Association of immune-related expression profile with sensitivity to chemotherapy in esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop | 2023 |
Induction of Kallikrein-Related Peptidase 13 and TET2/3 by Anticancer Drugs and Poor Prognosis of Patients with Esophageal Squamous Cell Carcinoma After Preoperative Treatment.
Topics: Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dioxygenases; DNA-Binding Proteins; Esophageal | 2024 |
[A Case of Esophageal Cancer with Multiple Lung Metastases Resected after Stent Placement and Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2023 |
Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deglutiti | 2019 |
Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxe | 2019 |
Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophagea | 2019 |
Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies | 2019 |
Tex10 promotes stemness and EMT phenotypes in esophageal squamous cell carcinoma via the Wnt/β‑catenin pathway.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Pro | 2019 |
MicroRNA-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id-1.
Topics: Adult; Aged; Animals; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Esophageal Neoplas | 2019 |
THUMP domain containing 2 protein possibly induces resistance to cisplatin and 5-fluorouracil in in vitro human esophageal squamous cell carcinoma cells as revealed by transposon activation mutagenesis.
Topics: Alleles; Cell Line, Tumor; Cisplatin; DNA Transposable Elements; Dose-Response Relationship, Drug; D | 2019 |
Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neu | 2020 |
Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophage | 2020 |
YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2020 |
Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; | 2020 |
Anti-EGFR plus chemotherapy in unselected advanced oesophageal squamous cell carcinoma: less POWERful than expected.
Topics: Cisplatin; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; H | 2020 |
GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cel | 2020 |
[A Case of Esophageal Cancer Achieving a Pathological Complete Response after Preoperative Docetaxel, Cisplatin, and 5-Fluorouracil Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Es | 2019 |
[A Case of Lymph Node Recurrence with Invasion to the Trachea after the Resection of Esophageal Cancer Treated by Multidisciplinary Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Sq | 2019 |
Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2020 |
Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Down-Regulation; | 2020 |
Nicotinamide N-methyltransferase decreases 5-fluorouracil sensitivity in human esophageal squamous cell carcinoma through metabolic reprogramming and promoting the Warburg effect.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cellular | 2020 |
RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Chemoradiother | 2022 |
A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2020 |
Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; D | 2021 |
Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2020 |
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2020 |
A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel | 2021 |
The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2021 |
Diethylhexyl phthalate (DEHP) regulates the proliferation and chemosensitivity of esophageal squamous cell carcinoma cells via regulation of PTEN.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Diethylhexyl Phthalate; Dise | 2021 |
NOTCH3 limits the epithelial-mesenchymal transition and predicts a favorable clinical outcome in esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2021 |
Serum IgG level is a predicting factor for the response to neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous | 2021 |
All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma.
Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Mov | 2017 |
A novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cell line Eca-109/5-FU with significant drug resistance-related characteristics.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resista | 2017 |
EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; ErbB Receptors; Esophageal | 2017 |
Treatment of esophageal cancer with radiation therapy -a pan-Chinese survey of radiation oncologists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvan | 2017 |
Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: A propensity-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2017 |
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2018 |
Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Es | 2018 |
Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2018 |
Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2017 |
With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Consolida | 2018 |
Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2018 |
Enteral nutrition and quality of life in patients undergoing chemoradiotherapy for esophageal carcinoma: a comparison of nasogastric tube, esophageal stent, and ostomy tube feeding.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deglutiti | 2018 |
Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2018 |
Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Esophageal Neopl | 2018 |
[A Case of Myocardial Metastasis of Esophageal Squamous Cell Carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2018 |
Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; | 2018 |
Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Esoph | 2018 |
Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Case-Control Studie | 2018 |
Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma.
Topics: Aged; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Esophageal Squamou | 2018 |
Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esoph | 2018 |
Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cell Line, T | 2018 |
The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Mod | 2018 |
Contribution of KCTD12 to esophageal squamous cell carcinoma.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromatin Assembly and Disas | 2018 |
[Definitive Radiotherapy for Esophageal Squamous Cell Carcinoma after Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning of Total Body Irradiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Esophageal Neoplasms; | 2018 |
Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem | 2019 |
Tetrahydrocurcumin, Curcumin, and 5-Fluorouracil Effects on Human Esophageal Carcinoma Cells.
Topics: Antineoplastic Agents; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Drug Screenin | 2019 |
The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Cardiotoxicity; Chemoradi | 2019 |
The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2019 |
Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Esophageal Neoplasms; | 2019 |
miR-145 Regulates the sensitivity of esophageal squamous cell carcinoma cells to 5-FU via targeting REV3L.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding P | 2019 |
Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 2020 |
Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer.
Topics: Adult; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Comb | 2019 |
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination | 2019 |
Safety of thoracoscopic esophagectomy after induction chemotherapy for locally advanced unresectable esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Ca | 2020 |
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemor | 2020 |
Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
Topics: Aged; B7-H1 Antigen; Biomarkers, Tumor; CD8-Positive T-Lymphocytes; Cisplatin; Disease-Free Survival | 2019 |
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
Significance of GSTP1 for predicting the prognosis and chemotherapeutic efficacy in esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemotherapy, Adj | 2013 |
Stem cell-like side populations in esophageal cancer: a source of chemotherapy resistance and metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2014 |
Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell L | 2013 |
TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug-Related Side Effects and | 2013 |
[A case of esophageal squamous cell carcinoma with submucosal tumor-like tumor due to direct invasion of the gastric wall].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; E | 2013 |
A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; C | 2014 |
Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Asian People; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Esophageal Squamous C | 2014 |
The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Growth Processes; Cel | 2014 |
Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2015 |
p38δ MAPK phenotype: an indicator of chemotherapeutic response in oesophageal squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cel | 2015 |
[A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell | 2014 |
Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Esophag | 2014 |
Assessment of insulin-like growth factor 1 receptor as an oncogene in esophageal squamous cell carcinoma and its potential implication in chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; C | 2014 |
Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Ce | 2014 |
Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Doxorub | 2015 |
Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2014 |
Combination of SNX-2112 with 5-FU exhibits antagonistic effect in esophageal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Drug Antagonism | 2015 |
Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity.
Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; DNA Methylation; Drug Resi | 2015 |
MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor | 2014 |
Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2014 |
Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Drug Administration | 2015 |
Semi-radical chemoradiotherapy for 53 esophageal squamous cell carcinomas with supraclavicular lymph node metastasis in a single institutional retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; D | 2014 |
Nimotuzumab with cisplatin or fluorouracil on human esophageal squamous cell carcinoma EC1 cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcin | 2015 |
Induction Chemotherapy Using FAP for Patients with Stage II/III Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2015 |
Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control | 2015 |
Salvage pharyngolaryngectomy with total esophagectomy following definitive chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cel | 2015 |
The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance.
Topics: Binding, Competitive; Carcinoma, Squamous Cell; Cdc20 Proteins; Cell Line, Tumor; Cell Proliferation | 2016 |
Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2016 |
Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2016 |
[A Case of Solitary Brain Metastasis from Stage 0 Esophageal Carcinoma after Neoadjuvant Chemotherapy Followed by Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Cisplatin | 2015 |
Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2016 |
Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2015 |
Second-Line Modified FOLFOX6 Regimen in The Patients with Metastatic Esophagus Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Admin | 2017 |
Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2016 |
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2017 |
Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review.
Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2016 |
Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2016 |
The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Carcinoma, | 2017 |
Radiation field size and dose determine oncologic outcome in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Pro | 2016 |
Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway.
Topics: Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Syne | 2016 |
Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2017 |
[Preoperative Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2016 |
Continuous infusion of a large dose of CF (folinic acid) and 5-FU combined with CDDP in the treatment of advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Di | 2017 |
THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcino | 2012 |
VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2012 |